ArticleACS omega2024
Hyaluronic Acid-Modified Luteolin-Copper Complex Nanodelivery System for Bacterial Prostatitis.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in hyaluronic acid-based biomaterials: applications in cancer therapy, wound healing, and disease management.Journal of materials science. Materials in medicine · 2025Review
- The Nanocarrier Landscape─Evaluating Key Drug Delivery Vehicles and Their Capabilities: A Translational Perspective.ACS applied materials & interfaces · 2025Review
- Targeted Sustained-Release Therapy for Vulnerable Atherosclerotic Plaques Using Luteolin-Loaded Nanoparticles.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial prostatitis is a common disease of the male genitourinary system, which seriously affects the normal life and health of male patients. Antibiotics are commonly used in the clinical treatment of bacterial prostatitis, but the efficacy of fluoroquinolones is gradually declining due to the increasing drug resistance of bacteria. Hence, it is necessary to find new antibacterial drugs to treat bacterial prostatitis. Luteolin is a natural flavonoid compound with many pharmacological activities such as antibacterial and anti-inflammatory activities, but its poor water solubility and low structural stability seriously limit its clinical application. In this study, we designed a targeting drug delivery system via a luteolin-copper complex grafted with hyaluronic acid. The results of the characterization proved the successful synthesis of the system. The results of the in vitro performance test show that the system has a good antibacterial effect and excellent blood compatibility and can be effectively released under different pH conditions. The prepared nanodrug delivery system not only provides a new idea for the treatment of bacterial prostatitis but also lays a theoretical and practical foundation for the wide application of luteolin in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.